Role of TNF-α in renal damage in mice showing hepatic steatosis induced by high fat diet

Hormone and Metabolic Research

Volumn 45, Issue 1, 2013, Pages 38-42

  Lai, Y H ^a,b   Chen, L J ^c   Cheng, J T ^b,d  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

etanercept; hepatic steatosis; PPAR ; renal damage; TNF

Indexed keywords

CHOLESTEROL; CREATININE; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FATTY LIVER; HISTOPATHOLOGY; KIDNEY INJURY; LIPID DIET; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

ACRIDINES; ANIMALS; BLOOD UREA NITROGEN; CREATININE; DIET, HIGH-FAT; FATTY LIVER; IMMUNOGLOBULIN G; KIDNEY; KIDNEY FUNCTION TESTS; LIPIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; PPAR DELTA; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84872343166     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1321871     Document Type: Article

References (36)

1. Neuschwander-Tetri B. A., Caldwell S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology: 2003; 37 1202 1219 (Pubitemid 36538699)
2. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol: 2006; 45 600 606 (Pubitemid 44307393)
3. Sanyal A. J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology: 2002; 123 1705 1725 (Pubitemid 35231670)
4. Lewis J. R., Mohanty S. R. Nonalcoholic fatty liver disease: a review and update. Digest Dis Sci: 2010; 55 560 578
5. Kalaitzidis R. G., Siamopoulos K. C. The role of obesity in kidney disease: recent findings and potential mechanisms. Int Urol Nephrol: 2011; 43 771 784
6. Yun K. E., Shin C. Y., Yoon Y. S., Park H. S. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis: 2009; 205 533 537
7. Targher G., Kendrick J., Smits G., Chonchol M. Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr Metab Cardiovasc Dis: 2010; 20 583 590
8. Targher G., Bosworth C., Kendrick J., Smits G., Lippi G., Chonchol M. Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Clin Chem Lab Med: 2009; 47 1055 1062
9. Targher G., Bertolini L., Chonchol M., Rodella S., Zoppini G., Lippi G., Zenari L., Bonora E. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia: 2010; 53 1341 1348
10. Targher G., Bertolini L., Rodella S., Zoppini G., Lippi G., Day C., Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia: 2008; 51 444 450
11. Yilmaz Y., Alahdab Y. O., Ozdogan O., Dolar E. Non-alcoholic fatty liver disease and microalbuminuria in non-diabetic patients: role of insulin resistance. Int Med J: 2009; 39 709 710
12. Targher G., Bertolini L., Rodella S., Lippi G., Zoppini G., Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol: 2010; 5 2166 2171
13. Machado M. V., Goncalves S., Carepa F., Coutinho J., Costa A., Cortez-Pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int: 2012; 32 241 248
14. Schupp M., Lazar M. A. Endogenous ligands for nuclear receptors: digging deeper. J Biol Chem: 2010; 285 40409 40415
15. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev: 1999; 20 649 688 (Pubitemid 30650602)
16. Cowherd R. M., Lyle R. E., McGehee R. E. Jr. Molecular regulation of adipocyte differentiation. Sem Cell Develop Biol: 1999; 10 3 10 (Pubitemid 129505533)
17. Staels B., Maes M., Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med: 2008; 5 542 553
18. Zandbergen F., Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta: 2007; 1771 972 982
19. Adkins Y., Kelley D. S. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem: 2010; 21 781 792
20. Rosenson R. S. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther: 2008; 6 1319 1330
21. Glass C. K., Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol: 2010; 10 365 376
22. Odegaard J. I., Ricardo-Gonzalez R. R., Goforth M. H., Morel C. R., Subramanian V., Mukundan L., Red Eagle A., Vats D., Brombacher F., Ferrante A. W., Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature: 2007; 447 1116 1120 (Pubitemid 47014427)
23. Moller D. E., Berger J. P. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Rel Metab Disord: 2003; 27 03 S17 S21 (Pubitemid 38019182)
24. Yang T., Michele D. E., Park J., Smart A. M., Lin Z., Brosius F. C. 3rd, Schnermann J. B., Briggs J. P. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol: 1999; 277 F966 F973 (Pubitemid 30046072)
25. Collino M., Benetti E., Miglio G., Castiglia S., Rosa A. C., Aragno M., Thiemermann C., Fantozzi R. Peroxisome proliferator-activated receptor beta/delta agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Rad Biol Med: 2011; 50 345 353
26. Uysal S., Armutcu F., Aydogan T., Akin K., Ikizek M., Yigitoglu M. R. Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. Clin Biochem: 2011; 44 1375 1379
27. Lee T. I., Kao Y. H., Chen Y. C., Pan N. H., Chen Y. J. Oxidative stress and inflammation modulate peroxisome proliferator-activated receptors with regional discrepancy in diabetic heart. Eur J Clin Invest: 2010; 40 692 699
28. Pang M., de la Monte S. M., Longato L., Tong M., He J., Chaudhry R., Duan K., Ouh J., Wands J. R. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol: 2009; 50 1192 1201
29. Hsieh T. J., Zhang S. L., Filep J. G., Tang S. S., Ingelfinger J. R., Chan J. S. High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology: 2002; 143 2975 2985 (Pubitemid 34809870)
30. Eccleston H. B., Andringa K. K., Betancourt A. M., King A. L., Mantena S. K., Swain T. M., Tinsley H. N., Nolte R. N., Nagy T. R., Abrams G. A., Bailey S. M. Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxide bioavailability, and modifies the mitochondrial proteome in mice. Antioxid Redox Signal: 2011; 15 447 459
31. Mauer S. M., Steffes M. W., Brown D. M. The kidney in diabetes. Am J Med: 1981; 70 603 612 (Pubitemid 11113956)
32. Das S. K., Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease. Indian J Clin Biochem: 2011; 26 202 209
33. Guzik T. J., Mangalat D., Korbut R. Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol: 2006; 57 505 528 (Pubitemid 46096102)
34. Silva L. C., Ortigosa L. C., Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy: 2010; 2 817 833
35. Liang Y. J., Jian J. H., Liu Y. C., Juang S. J., Shyu K. G., Lai L. P., Wang B. W., Leu J. G. Advanced glycation end products-induced apoptosis attenuated by PPARdelta activation and epigallocatechin gallate through NF-kappaB pathway in human embryonic kidney cells and human mesangial cells. Diabetes/Metab Res Rev: 2010; 26 406 416
36. 2-induced cell death by S-ketoprofen in renal cells. Pharmacol Res: 2007; 55 295 302 (Pubitemid 46518160)